eli lilly retatrutide press release 2024 2025 is now pharma's top revenue company. It just got FDA approval for an oral GLP-1, but Wall Street isn't celebrating Retatrutide, Eli Lilly's next obesity

Utilization data, outcomes, and adherence all flowing back through Serve You Rx to the employer

Unlike peptide-based incretins, this is a Small Molecule Inhibitor targeting the cytosolic enzyme Nicotinamide N-methyltransferase (NNMT)

Higher doses amplify GLP-1 receptor activity in areas of the brain, like the Area Postrema, which is responsible for triggering nausea

The transdermal compositions instantly achieve steady state in rats and the concentration is sustained over at least 12 hrs, preferably over 24 hrs

Published incidence figures for B12 deficiency after sleeve gastrectomy range from 0% to over 36%, with deficiency sometimes not appearing until two years after surgery (3)